Tag: orphan drug
Sartar received Orphan Drug Designation for soft tissue sarcomas from the FDA
As published last week, we are very proud to announce that Sartar was recently granted an new orphan drug designation (ODD) by the U.S. Food & Drug Administration (FDA) for the treatment of soft tissue sarcomas using our SAR003 drug candidate. This is a great milestone for our team and a significant regulatory protection for […]
International Rare Disease Day
Today is the Rare Disease Day, a day dedicated to raising awareness about the many rare disease types that, while individually uncommon, collectively impact a significant number of patients worldwide. Among these are several rare cancers like soft tissue sarcomas including leiomyosarcoma, liposarcoma, and of course gastrointestinal stromal tumors (GIST), each presenting unique challenges in […]
Sartar received Orphan Drug Designation from the FDA
We are delighted to announce that Sartar Therapeutics received Orphan Drug Designation for GIST from the U.S. Food & Drug administration (FDA). This is a great addition to our Orphan Drug Designation in EU granted by the European Medicines Agency (EMA) earlier this year. See Orphan Drug Designation in FDA’s database.
Sartar received Orphan Drug Designation in EU
We are pleased to announce that Sartar Therapeutics has been granted orphan drug designation in EU by the European Commission. See more on Community Register of orphan medicinal products.